Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials
出版年份 2021 全文链接
标题
Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials
作者
关键词
-
出版物
Frontiers in Immunology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-12-07
DOI
10.3389/fimmu.2021.795574
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis
- (2021) Jingyi Tong et al. NEUROLOGICAL SCIENCES
- Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis
- (2021) Tamara Pérez-Jeldres et al. DRUGS
- Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2021) Xin Wu et al. Frontiers in Pharmacology
- Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis
- (2021) Amirreza Naseri et al. Multiple Sclerosis and Related Disorders
- First‐line therapies in late‐onset multiple sclerosis: An Italian registry study
- (2021) Aurora Zanghì et al. EUROPEAN JOURNAL OF NEUROLOGY
- Cognition and disease characteristics in adult onset versus late onset multiple sclerosis
- (2021) Rachel Butler Pagnotti et al. Multiple Sclerosis Journal
- Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis
- (2020) Elyse Swallow et al. Journal of Comparative Effectiveness Research
- Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of Immunotherapies
- (2020) Oliver Findling et al. Journal of Clinical Medicine
- A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes
- (2020) Volker Limmroth et al. Frontiers in Neurology
- Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
- (2020) Helmut Butzkueven et al. BMJ Open
- Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis
- (2020) Bruce A. C. Cree et al. JAMA Neurology
- Incidence of myocardial injury in coronavirus disease 2019 (COVID-19): a pooled analysis of 7,679 patients from 53 studies
- (2020) Zhi-Chun Gu et al. Cardiovascular Diagnosis and Therapy
- Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
- (2020) Jerold Chun et al. DRUGS
- Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis
- (2019) Zhi-Chun Gu et al. Clinical Gastroenterology and Hepatology
- Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects
- (2019) Pierre-Eric Juif et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis
- (2019) Claudia Volpi et al. Expert Opinion on Drug Discovery
- Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
- (2019) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
- (2019) Giancarlo Comi et al. LANCET NEUROLOGY
- The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta‐analysis
- (2019) Ting Yang et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Late onset and young onset relapsing remitting multiple sclerosis. Evidence from a retrospective long-term follow-up study
- (2018) Emanuele D'Amico et al. EUROPEAN JOURNAL OF NEUROLOGY
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Multiple Sclerosis
- (2018) Daniel S. Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Course of Multiple Sclerosis
- (2018) Sylvia Klineova et al. Cold Spring Harbor Perspectives in Medicine
- A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future
- (2018) Mehrdad Gholamzad et al. INFLAMMATION RESEARCH
- Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator
- (2017) Jonathan Q. Tran et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
- (2017) Giancarlo Comi et al. JOURNAL OF NEUROLOGY
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
- (2016) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
- (2016) Alice Laroni et al. NEUROLOGICAL SCIENCES
- Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
- (2015) Adnan M. Subei et al. CNS DRUGS
- Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm
- (2015) Sonja Krösser et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study
- (2015) Damiano Paolicelli et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis
- (2014) Yara Dadalti Fragoso et al. ARQUIVOS DE NEURO-PSIQUIATRIA
- Vagomimetic Effects of Fingolimod: Physiology and Clinical Implications
- (2014) Emilio Vanoli et al. CNS Neuroscience & Therapeutics
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis
- (2014) Edward Fox et al. Multiple Sclerosis and Related Disorders
- First-dose effects of fingolimod: Pooled safety data from three phase 3 studies
- (2014) John P. DiMarco et al. Multiple Sclerosis and Related Disorders
- Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
- (2014) Ludwig Kappos et al. Multiple Sclerosis and Related Disorders
- Modulators of the Sphingosine 1-phosphate receptor 1
- (2013) Mariangela Urbano et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
- (2013) Ralf Gold et al. JOURNAL OF NEUROLOGY
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
- (2013) Krzysztof Selmaj et al. LANCET NEUROLOGY
- Early tolerability and safety of fingolimod in clinical practice
- (2012) Daniel Ontaneda et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis
- (2012) T Saida et al. Multiple Sclerosis Journal
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
- (2010) Jerold Chun et al. CLINICAL NEUROPHARMACOLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
- (2009) Alessandro Liberati et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More